Pfizer seeks approval to expand RSV vaccine to adults 18 and older
Pfizer says a clinical trial showed people between the ages of 18 to 59 had an immune response similar to the trial results for older adults.
Top Stories
Pearl River's Pfizer is looking to expand its respiratory syncytial virus (RSV) vaccine approval for Americans as young as 18.
The drug, Abryso, was approved for those over the age of 60 last year.
The Centers for Disease Control and Prevention say RSV is a common virus that usually causes mild, cold-like symptoms. Most people recover in a week or two, but RSV can be serious. Infants and older adults are more likely to develop severe RSV and need hospitalization.
Pfizer says a clinical trial showed people between the ages of 18 to 59 had an immune response similar to the trial results for older adults. The company says the vaccine was also well-tolerated and safe.
The results of the clinical trial have not been peer-reviewed or published in a medical journal yet, but Pfizer says it is planning to submit the data to the Food and Drug Administration.
